Exploring the Prognosis of Breast Cancer with Synchronous Distant Nonregional Lymph Node Metastasis and Establishing a Predictive Model: A Population-Based Study
Table 1
Demographic and clinicopathologic features of all included patients.
Characteristics
TnN3cM0 (%)
SDLNM (%)
Other oligometastasis (%)
value
Age
<0.001
≤50 y
186 (37.4)
218 (31.5)
2371 (28.4)
51-65 y
205 (41.2)
302 (43.6)
3631 (43.5)
66-80 y
106 (21.3)
172 (24.9)
2348 (28.1)
Race
<0.001
Caucasian
351 (70.6)
481 (69.5)
6364 (76.2)
Black/AI
108 (21.7)
135 (19.5)
1371 (16.4)
Asian
38 (7.6)
76 (11.0)
615 (7.4)
Marriage
0.506
Married
256 (51.5)
343 (49.6)
4082 (48.9)
Single and unknown
241 (48.5)
349 (50.4)
4268 (51.1)
Histology
<0.001
IDC
402 (80.9)
556 (80.3)
6056 (72.5)
Non-IDC
95 (19.1)
136 (19.7)
2294 (27.5)
SBR grade
<0.001
Grade 3
255 (51.3)
335 (48.4)
2462 (29.5)
Grade 1-2
126 (25.4)
184 (26.6)
3651 (43.7)
Unknown
116 (23.3)
173 (25.0)
2237 (26.8)
T stage
<0.001
T0-1
73 (14.7)
102 (14.7)
1247 (14.9)
T2
163 (32.8)
207 (29.9)
3266 (39.1)
T3
93 (18.7)
107 (15.5)
1607 (19.2)
T4
168 (33.8)
276 (39.9)
2230 (26.7)
Subtype
<0.001
Luminal A
174 (35.0)
288 (41.6)
5531 (66.2)
Luminal B
113 (22.7)
127 (18.4)
1368 (16.4)
Her2 + HR-
82 (16.5)
99 (14.3)
564 (6.8)
TNBC
128 (25.8)
178 (25.7)
887 (10.6)
Surgery
<0.001
None
95 (19.1)
271 (39.2)
4857 (58.2)
Lumpectomy
87 (17.5)
101 (14.6)
1057 (12.7)
Mastectomy
315 (63.4)
320 (46.2)
2436 (29.2)
Radiotherapy
<0.001
Yes
293 (59.0)
247 (35.7)
2133 (25.5)
No
204 (41.0)
445 (64.3)
6217 (74.5)
Chemotherapy
<0.001
Yes
463 (93.2)
578 (83.5)
5013 (60.0)
No
34 (6.8)
114 (16.5)
3337 (40.0)
SDLNM: synchronous isolated distant lymph node metastasis; Her2: human epidermal growth factor receptor type 2; AI: American Indian; HR: hormone receptor; IDC: infiltrating duct carcinoma; SBR grade: Scarff-Bloom-Richardson grading system; TNBC: triple-negative breast cancer.
